295 related articles for article (PubMed ID: 29152737)
1. Molecular mechanisms of drug resistance in ovarian cancer.
Norouzi-Barough L; Sarookhani MR; Sharifi M; Moghbelinejad S; Jangjoo S; Salehi R
J Cell Physiol; 2018 Jun; 233(6):4546-4562. PubMed ID: 29152737
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic Pathways Offer Targets for Ovarian Cancer Treatment.
Gyparaki MT; Papavassiliou AG
Clin Breast Cancer; 2018 Jun; 18(3):189-191. PubMed ID: 29042129
[No Abstract] [Full Text] [Related]
3. Molecular mechanisms of platinum‑based chemotherapy resistance in ovarian cancer (Review).
Yang L; Xie HJ; Li YY; Wang X; Liu XX; Mai J
Oncol Rep; 2022 Apr; 47(4):. PubMed ID: 35211759
[TBL] [Abstract][Full Text] [Related]
4. Deciphering the Molecular Mechanisms behind Drug Resistance in Ovarian Cancer to Unlock Efficient Treatment Options.
Nunes M; Bartosch C; Abreu MH; Richardson A; Almeida R; Ricardo S
Cells; 2024 May; 13(9):. PubMed ID: 38727322
[TBL] [Abstract][Full Text] [Related]
5. Stress-Adaptive Response in Ovarian Cancer Drug Resistance: Role of TRAP1 in Oxidative Metabolism-Driven Inflammation.
Amoroso MR; Matassa DS; Agliarulo I; Avolio R; Maddalena F; Condelli V; Landriscina M; Esposito F
Adv Protein Chem Struct Biol; 2017; 108():163-198. PubMed ID: 28427560
[TBL] [Abstract][Full Text] [Related]
6. The influence of long non-coding RNAs on the response to chemotherapy in ovarian cancer.
Wambecke A; Ahmad M; Lambert B; Joly F; Poulain L; Denoyelle C; Meryet-Figuiere M
Gynecol Oncol; 2020 Mar; 156(3):726-733. PubMed ID: 31883617
[TBL] [Abstract][Full Text] [Related]
7. NANOG regulates epithelial-mesenchymal transition and chemoresistance through activation of the STAT3 pathway in epithelial ovarian cancer.
Liu S; Sun J; Cai B; Xi X; Yang L; Zhang Z; Feng Y; Sun Y
Tumour Biol; 2016 Jul; 37(7):9671-80. PubMed ID: 26801672
[TBL] [Abstract][Full Text] [Related]
8. MiR-1294 confers cisplatin resistance in ovarian Cancer cells by targeting IGF1R.
Zhang Y; Huang S; Guo Y; Li L
Biomed Pharmacother; 2018 Oct; 106():1357-1363. PubMed ID: 30119207
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-mediated drug resistance in ovarian cancer.
Mihanfar A; Fattahi A; Nejabati HR
J Cell Physiol; 2019 Apr; 234(4):3180-3191. PubMed ID: 28628227
[TBL] [Abstract][Full Text] [Related]
10. The potential role of miRNAs and exosomes in chemotherapy in ovarian cancer.
Alharbi M; Zuñiga F; Elfeky O; Guanzon D; Lai A; Rice GE; Perrin L; Hooper J; Salomon C
Endocr Relat Cancer; 2018 Dec; 25(12):R663-R685. PubMed ID: 30400025
[TBL] [Abstract][Full Text] [Related]
11. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
[TBL] [Abstract][Full Text] [Related]
12. Identification and validation of differentially expressed proteins in epithelial ovarian cancers using quantitative proteomics.
Qu H; Chen Y; Cao G; Liu C; Xu J; Deng H; Zhang Z
Oncotarget; 2016 Dec; 7(50):83187-83199. PubMed ID: 27825122
[TBL] [Abstract][Full Text] [Related]
13. miRNAs and ovarian cancer: a miRiad of mechanisms to induce cisplatin drug resistance.
Samuel P; Pink RC; Brooks SA; Carter DR
Expert Rev Anticancer Ther; 2016; 16(1):57-70. PubMed ID: 26567444
[TBL] [Abstract][Full Text] [Related]
14. Micro-RNAs associated with the evolution of ovarian cancer cisplatin resistance.
Boac BM; Xiong Y; Marchion DC; Abbasi F; Bush SH; Ramirez IJ; Khulpateea BR; Clair McClung E; Berry AL; Bou Zgheib N; Chon HS; Shahzad MM; Judson PL; Wenham RM; Apte SM; Berglund AE; Magliocco AM; Lancaster JM
Gynecol Oncol; 2016 Feb; 140(2):259-63. PubMed ID: 26731723
[TBL] [Abstract][Full Text] [Related]
15. Drug resistance in ovarian cancer: the emerging importance of gene transcription and spatio-temporal regulation of resistance.
Richardson A; Kaye SB
Drug Resist Updat; 2005 Oct; 8(5):311-21. PubMed ID: 16233989
[TBL] [Abstract][Full Text] [Related]
16. Targeting Epithelial-Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer.
Du B; Shim JS
Molecules; 2016 Jul; 21(7):. PubMed ID: 27455225
[TBL] [Abstract][Full Text] [Related]
17. Molecular diagnosis and molecular profiling to detect treatment-resistant ovarian cancer.
English DP; Menderes G; Black J; Schwab CL; Santin AD
Expert Rev Mol Diagn; 2016 Jul; 16(7):769-82. PubMed ID: 27169329
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of miR-503 contributes to the development of drug resistance in ovarian cancer by targeting PI3K p85.
Wu D; Lu P; Mi X; Miao J
Arch Gynecol Obstet; 2018 Mar; 297(3):699-707. PubMed ID: 29327155
[TBL] [Abstract][Full Text] [Related]
19. Overcoming cisplatin resistance of ovarian cancer cells by targeting HIF-1-regulated cancer metabolism.
Ai Z; Lu Y; Qiu S; Fan Z
Cancer Lett; 2016 Apr; 373(1):36-44. PubMed ID: 26801746
[TBL] [Abstract][Full Text] [Related]
20. miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.
van Jaarsveld MT; Helleman J; Boersma AW; van Kuijk PF; van Ijcken WF; Despierre E; Vergote I; Mathijssen RH; Berns EM; Verweij J; Pothof J; Wiemer EA
Oncogene; 2013 Sep; 32(36):4284-93. PubMed ID: 23045278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
